Bentham Science Publishers

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology.

The seventh volume of this series features reviews that cover the following topics related to the treatment of neurodegenerative diseases, epilepsy and stroke:

- Fatty Acid Amides as a New Potential Therapeutic Agent in Multiple Sclerosis

- Epileptic Seizures Detection Based on Non-Linear Characteristics Coupled with Machine Learning Techniques

- Hampering Essential Tremor Neurodegeneration in Essential Tremor: Present and Future Directions

- The Potential Therapeutic Role of the Melatoninergic System in Treatment of Epilepsy and Comorbid Depression

- Modeling Neurodegenerative Diseases Using Transgenic Model of Drosophila

- Genetic Basis in Stroke Treatment: Targets of Potent Inhibitors

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology.

The ninth volume of this series features reviews that cover the following topics related to the treatment of a different CNS disorders, related diseases and basic neuropharmacology research:

- Integrating imaging and microdialysis into systems neuropharmacology

- Depression heterogeneity and the potential of a transdiagnostic and dimensional approach to identify biologically relevant phenotypes

- CAR-T cells in brain tumors and autoimmune diseases – from basics to the clinic

- Revaluation of thyrotropin-releasing hormone and its mimetics as candidates for treating a wide range of neurological and psychiatric disorders

- Natural BACE1 inhibitors: promising drugs for the management of Alzheimer's disease

- The possibilities of safe lithium therapy in the treatment of neurological and psychoemotional disorders

- Pharmacotherapy of multiple sclerosis and treatment strategies

Among neurodegenerative diseases, those that lead to a state of dementia are the aim of several investigations. Dementia is a chronic disease the prevalence of which is increasing worldwide. The number of dementia patients in the world is approximately 50 million, and it is estimated that the number of patients will reach 131.5 million by 2050. This increase will be accompanied by a significant increase in medical expenditures and other expenses, especially for elderly patients. Therefore, the maintenance cost of dementia in the future is expected to be quite high. For this reason, several investigations aim, firstly, to describe the key mechanisms involved in the origin of dementia and, secondly, to establish preventive and therapeutic strategies in order to understand and mitigate this debilitating pathology.

This volume of Frontiers in Clinical Drug Research - Dementia explores the current comorbidities that cause cognitive impairment and the current management alternatives for clinical cases of dementia. The reviews contributed in these volume will provide readers with a current perspective on the subject. The topics covered in this volume include:

- Comorbidities inducing mild cognitive impairment - an evaluation of the risk caused by some pathological conditions

- Tau-targeted therapy in Alzheimer's disease - history and current state

- Emerging nanotherapeutic strategies in Alzheimer's disease

- Implication of dehydroepiandrosterone on dementia related to oxidative stress

- Polyphenol compounds as potential therapeutic agents in Alzheimer’s disease

The volume is a timely update on dementia treatment for clinical physicians, neurologists, gerontologists, pharmaceutical and medicinal chemistry researchers, and physiologists.

Frontiers in Clinical Drug Research – Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research.

The second volume of this series features 7 reviews presenting updates on hormones and several classes of drugs:

-Osteocalcin action in glucose metabolism

-Sodium-glucose co-transporter 2 (SGLT2) inhibitors

-Glucagon-like peptide-1 (GLP-1) mimetics

-Dipeptidyl peptidase 4 (DPP-4) inhibitors

-New drugs in clinical trial and commercial phases

Frontiers in Clinical Drug Research – Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research.

The fourth volume of this series features 7 chapters:

-Pharmacologic Obesity Treatment

-Interplay Between Bile Acid and GLP-1 Receptor Agonist Signaling Informs the Design of Drugs to Combat Obesity and its Metabolic Complications

-Sodium–Glucose Co-Transporters Inhibitors for Type 2 Diabetes Mellitus

-The Effects of Traditional Chinese Medicine on Inflammatory Cytokines in Diabetic Nephropathy

-Through the Perspective of Histology – The Alzheimer’s Disease Promotion by Obesity and Glucose Metabolism: Type 3 Diabetes

-Pharmacological Mechanism of PPARγ Ratio in Diabetes and Obesity

-Hydrogen Sulfide and Carbohydrate Metabolism

Frontiers in Clinical Drug Research – Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research.

The sixth volume of this series features 6 reviews which are informative guides to therapy and drug administration in diabetes and metabolic syndrome, for both the medical specialist and the pharmacologist.

- The failing heart in diabetes with special emphasis on prevention

- Flavonoids as prominent anti-diabetic agents

- Chemosensor in glucose monitoring, advances and challenges

- Synergistic drugs and polyherbal formulations for obesity: current status and future prospectives

- Urge for herbal anti-diabetic medicines towards clinical and therapeutic implications

- Curcuma longa as dietary supplement and diabetes mellitus: evidence from experimental studies

Frontiers in Clinical Drug Research – HIV is an eBook series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of acquired immune deficiency syndrome (AIDS) and other disorders associated with human immunodeficiency virus (HIV) infection. The scope of the eBook series covers a range of topics including the medicinal chemistry and pharmacology of natural and synthetic drugs employed in the treatment of AIDS (including HAART) and resulting complications, and the virology and immunological study of HIV and related viruses. Frontiers in Clinical Drug Research – HIV is a valuable resource for pharmaceutical scientists, clinicians and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in HIV/AIDS research.

The first volume of this series features 7 chapters that cover a variety of topics including:

-Antiretroviral drug development

-HIV-1 genomics

-HIV drug targets such as ribosomes and HIV Integrase

-HAART associated nephrotoxicity

Frontiers in Clinical Drug Research - HIV is an eBook series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of acquired immune deficiency syndrome (AIDS) and other disorders associated with human immunodeficiency virus (HIV) infection. The scope of the eBook series covers a range of topics including the medicinal chemistry and pharmacology of natural and synthetic drugs employed in the treatment of AIDS (including HAART) and resulting complications, and the virology and immunological study of HIV and related viruses. Frontiers in Clinical Drug Research - HIV is a valuable resource for pharmaceutical scientists, clinicians and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in HIV/AIDS research.

The third volume of this series features 5 chapters that cover a variety of topics including:

- Studies of HPV infections in HIV positive people

- Allosteric Integrase Inhibitors

- HAART

- Drugs targeting various types HIV-1 enzymes

Frontiers in Clinical Drug Research – HIV is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of acquired immune deficiency syndrome (AIDS) and other disorders associated with human immunodeficiency virus (HIV) infection. The scope of the book series covers a range of topics including the medicinal chemistry and pharmacology of natural and synthetic drugs employed in the treatment of AIDS (including HAART) and resulting complications, and the virology and immunological study of HIV and related viruses. Frontiers in Clinical Drug Research – HIV is a valuable resource for pharmaceutical scientists, clinicians and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in HIV/AIDS research.

The fifth volume of this series features 5 chapters that cover these topics:

- Clinical Eradication of Latent HIV Reservoirs: Where Are We Now?

- HIV-1 Genotypic Drug Resistance Testing and Next-Generation Sequencing

- Current and Promising Multiclass Drug Regimens and Long-Acting Formulation Drugs in HIV Therapy

- Role of Nanotechnology in HIV Diagnosis and Prognosis

- Preventive and Therapeutic Features of Combination Therapy for HIV